Autosomal recessive complex spastic paraplegia caused by mutations in CAPN1 is a rare inherited nerve disorder. It mainly makes the legs stiff and tight (spastic), so walking becomes hard. Many people also have poor balance and shaky movements (cerebellar ataxia). Symptoms usually start in the teenage years or adulthood and worsen slowly over time. The problem happens when both copies of the CAPN1 gene have harmful changes (mutations). The CAPN1 gene makes an enzyme called calpain-1, which helps nerve cells stay healthy and adjust their connections. When calpain-1 does not work well, long nerve fibers that control movement get sick, and balance pathways can also be affected. Cell+2SpringerLink+2

This condition is a rare, inherited nerve-fiber disorder. “Autosomal recessive” means a person develops the disease when both copies of the CAPN1 gene have disease-causing variants. CAPN1 encodes calpain-1, a calcium-activated protease involved in neuron signaling and axonal health. Loss-of-function variants lead to slowly progressive stiffness (spasticity) and weakness of the legs, often with “complex” features like cerebellar ataxia (poor balance/coordination), dysarthria, or other neurologic signs. Onset can vary from childhood to adulthood. There is no cure yet; care focuses on relieving symptoms, maintaining mobility, and preventing complications. Orpha+3PMC+3ScienceDirect+3

Researchers first recognized CAPN1 as a cause of HSP in families with spastic paraplegia type 76 (SPG76). Case series across multiple populations show lower-limb spasticity with brisk reflexes and extensor plantar responses; many patients also have ataxia. Brain/spine MRI is often normal or shows mild cerebellar changes. Genetic testing confirms bi-allelic CAPN1 variants. Management is multidisciplinary: physical therapy, assistive devices, antispasticity medications, focal botulinum toxin for troublesome muscles, and in selected cases intrathecal baclofen or orthopedic procedures. nhs.uk+3ScienceDirect+3BioMed Central+3

Other names

• SPG76

• Autosomal recessive spastic paraplegia type 76

• CAPN1-related hereditary spastic paraplegia

• Spastic-ataxia due to CAPN1 (many patients have both spasticity and ataxia) Orpha+1

Types

Doctors use two broad type labels for hereditary spastic paraplegia:

1. Pure type – mainly leg stiffness and weakness.

2. Complex (or complicated) type – leg stiffness plus extra problems, like ataxia (poor balance), slurred speech, bladder issues, mild sensory loss, or mild learning problems.

Most people with CAPN1 mutations have the complex type with ataxia, but pure cases are also reported. This means the same gene can cause a spectrum, from “mostly spastic” to “spastic-ataxic.” Frontiers+1

---

Causes

For this disease, the root cause is biallelic (two-copy) mutations in CAPN1. Below are 20 ways we describe or understand those causes in medical genetics and biology. Each item is a short paragraph so it’s easy to follow.

1. Biallelic CAPN1 mutations
   You must inherit two harmful variants, one from each parent, to get the disease (autosomal recessive). Carriers (one variant) usually have no symptoms. Cell+1

2. Loss of calpain-1 function
   Most variants reduce or remove the enzyme’s activity, so nerve cells lose a tool they need for normal signaling and repair. SpringerLink

3. Missense variants
   A single “letter change” can swap one amino acid for another and weaken calpain-1’s cutting action. Many reported CAPN1 variants are missense. Wiley Online Library

4. Nonsense variants
   A premature “stop” signal can truncate the protein so it cannot work. preventiongenetics.com

5. Frameshift variants
   Small insertions or deletions can shift the reading frame, making a faulty protein that the cell often discards. preventiongenetics.com

6. Splice-site variants
   DNA changes near intron–exon borders can mis-splice the mRNA, removing key parts of the protein. preventiongenetics.com

7. Larger deletions/duplications
   Less common structural changes can remove or duplicate chunks of the gene, blocking normal protein production. preventiongenetics.com

8. Damage to calpain catalytic domain
   Some variants hit the enzyme’s “active site,” so it cannot cut its targets properly. Wiley Online Library

9. Calcium-binding disruption
   Calpain-1 needs calcium to turn on. Variants can disturb calcium-dependent activation. marrvel.org

10. Synaptic plasticity impairment
    Calpain-1 helps synapses adapt. Without it, movement circuits do not fine-tune well, contributing to spasticity and ataxia. SpringerLink

11. Neuroprotective pathway loss
    Calpain-1 has roles in protecting neurons from stress. Loss of that protection makes long motor tracts vulnerable. SpringerLink

12. Cerebellar development effects
    Animal and human studies link CAPN1 loss to cerebellar changes, which explains balance and coordination problems. Cell

13. Axonal maintenance failure
    Very long nerve fibers need constant maintenance. Without calpain-1 signaling, axons can degenerate slowly. SpringerLink

14. Protein-clearing imbalance
    Calpain-1 helps trim or activate proteins. If trimming fails, certain proteins accumulate or misbehave. marrvel.org

15. Founder variants in families/regions
    In some families or communities, one shared variant is passed through generations, raising local risk. (Reported across multiple cohorts.) PMC

16. Consanguinity increases risk
    Parents related by blood are more likely to carry the same rare variant, raising the chance a child inherits two copies. (General AR genetics principle reflected in SPG76 reports.) Cell

17. Modifier genes
    Other genes can shape how severe or complex the symptoms become, even with the same CAPN1 variant (inferred from variable phenotypes across families). ScienceDirect

18. Environmental stressors as aggravators
    Fever, illness, or deconditioning do not cause SPG76 but can worsen stiffness and balance temporarily.

19. Aging of long tracts
    With age, damaged pathways work less well, so symptoms tend to slowly progress. malacards.org

20. Rare pure-type mechanism
    Some CAPN1 variants mainly affect corticospinal tracts (spasticity) with little or no ataxia, producing a “pure” HSP picture. Frontiers

Symptoms

1. Leg stiffness (spasticity) – tight muscles make steps short and effortful. This is the core symptom. malacards.org

2. Leg weakness – climbing stairs and standing from a chair become hard over time. malacards.org

3. Scissoring gait – legs pull inward and cross while walking because inner thigh muscles are tight.

4. Tripping and falls – toes catch the ground due to stiffness and poor foot lift.

5. Ankle clonus – rhythmic jerks at the ankle when the foot is quickly flexed (doctor notices this).

6. Babinski sign – big toe goes up when the sole is stroked (a sign of upper motor neuron damage).

7. Poor balance (ataxia) – unsteady, wide-based walking, worse in the dark or on uneven ground. Orpha

8. Shaky arm movements – finger-to-nose testing may look wobbly; handwriting can get messy. ScienceDirect

9. Slurred speech (dysarthria) – words sound slow or slurred when the speech muscles are stiff or ataxic. malacards.org

10. Foot deformities – high arches or hammer toes can develop over years of abnormal tone. malacards.org

11. Bladder urgency – frequent urges or leakage because pathways that control bladder are affected. Orpha

12. Mild sensory loss – some people feel numbness or vibration loss in the feet. Orpha

13. Fatigue – walking with stiff legs takes extra energy, so people tire easily.

14. Cramps or spasms – sudden muscle tightness, especially at night or after exertion.

15. Variable onset and pace – usually teens to adulthood, with slow progression over many years. malacards.org

---

Diagnostic tests

Doctors diagnose SPG76 by combining history, examination, MRI, and genetic testing. Other tests help rule out look-alike problems or measure complications.

A) Physical examination (bedside observation)

1. Gait assessment
   The doctor watches you walk: stride length, leg crossing, toe drag, and balance. A spastic, scissoring gait with poor arm swing suggests HSP.

2. Tone testing
   They move your legs to feel “catching” and resistance that gets worse with faster movement—typical of spasticity.

3. Reflexes and Babinski
   Reflexes are brisk; tapping the knee gives a large kick. A positive Babinski (big toe up) supports upper-motor-neuron disease.

4. Strength pattern
   Hip flexion, knee extension, and ankle dorsiflexion are checked. Weakness plus spasticity explains falls and toe drag.

5. Cerebellar signs
   Heel-to-shin, finger-to-nose, and rapid alternating movements show ataxia if shaky or slow, which fits the complex type in many CAPN1 cases. Orpha

B) Manual/bedside coordination and balance tests

6. Tandem gait (heel-to-toe)
   Walking in a straight line highlights balance problems from cerebellar involvement.

7. Romberg test
   Standing with feet together, then closing eyes—more sway or a fall suggests balance pathway issues.

8. Timed Up and Go (TUG)
   Stand, walk 3 meters, turn, return, and sit. Time reflects real-world mobility and fall risk.

9. Spasticity scales (e.g., Modified Ashworth Scale)
   A quick manual grade of tone; helpful to monitor treatment effect over visits.

10. 9-Hole Peg / finger taps
    Simple hand tests to document mild upper-limb ataxia or spasticity that may accompany leg symptoms in SPG76. ScienceDirect

C) Laboratory and pathological tests

11. Genetic testing of CAPN1
    The key lab test. Sequencing looks for missense, nonsense, frameshift, and splice variants, and copy-number changes. Positive results confirm the cause and show autosomal-recessive inheritance in the family. preventiongenetics.com+1

12. HSP multigene panel or exome/genome
    Panels or exome/genome testing are useful because many genes can cause HSP. This increases the chance of finding the exact gene. PMC

13. Basic blood work (rule-out)
    B12, vitamin E, thyroid function, copper, CBC, and metabolic tests help exclude treatable mimics (for example, deficiency neuropathies) that can worsen stiffness and balance.

14. Creatine kinase (CK)
    Usually normal or mildly raised; helps separate primary muscle disease from a spinal tract problem.

15. Urine/serum studies for infections or inflammation (when indicated)
    These do not diagnose SPG76, but they look for other conditions that could temporarily worsen symptoms.

D) Electrodiagnostic tests

16. Nerve conduction studies (NCS)
    Often normal in pure HSP, but can show mild distal sensory changes in some SPG76 patients; helps rule out coexisting neuropathy. Orpha

17. Electromyography (EMG)
    Assesses muscle activation; mainly to exclude lower-motor-neuron or primary muscle disorders.

18. Evoked potentials (SSEPs/MEPs)
    Measure signal travel times in sensory and motor pathways. Delays support long-tract involvement seen in HSP.

E) Imaging tests

19. MRI brain
    Looks for cerebellar atrophy or other changes that fit the ataxia seen in many CAPN1 cases; also rules out structural lesions. Cell

20. MRI spinal cord
    Usually normal in HSP, but rules out compression, inflammation, or other spinal diseases that can mimic spasticity.

Non-pharmacological treatments (therapies & others

1. Regular physiotherapy (PT).
   PT keeps joints moving, stretches tight muscles, and trains strength, balance, and endurance. The goal is to lower spasticity’s daily impact, prevent contractures, and preserve safe walking. Mechanisms include repeated stretching (reduces reflex hyperexcitability), task-specific gait practice (neuroplasticity), and strengthening of weak antagonists. nhs.uk+2PMC+2

2. Occupational therapy (OT).
   OT teaches energy-saving techniques and adaptive strategies for dressing, bathing, writing, computer work, and kitchen tasks. The purpose is independence and safety at home and work. Mechanism: activity analysis + environmental modification + assistive tools to reduce the functional burden of spasticity. nhs.uk+1

3. Gait training & task-specific walking practice.
   Structured treadmill or over-ground practice with cues improves step symmetry, cadence, and endurance. Purpose: safer, more efficient walking and reduced falls. Mechanism: repeated, graded motor practice promotes central pattern re-training. Frontiers

4. Stretching & range-of-motion programs.
   Daily calf, hamstring, and hip-flexor stretching limits tendon/muscle shortening. Purpose: prevent contractures and toe-walking that worsen trips and falls. Mechanism: sustained stretch dampens stretch reflexes and maintains muscle-tendon length. PMC

5. Strength & core conditioning.
   Targeting hip extensors/abductors and ankle dorsiflexors helps counter spastic patterns; core work supports posture. Purpose: improve transfers, stair use, and fatigue. Mechanism: progressive resistance and motor-control training increase recruitment of underused muscles. Medscape

6. Ankle-foot orthoses (AFOs) & shoe inserts.
   Custom AFOs stabilize the ankle, reduce equinus/toe drag, and improve foot placement. Purpose: reduce falls and energy cost of walking. Mechanism: external alignment and controlled ankle motion. nhs.uk+1

7. Canes, crutches, or walkers.
   Mobility aids provide stability during uneven terrain or fatigue. Purpose: injury prevention and longer community ambulation. Mechanism: widen base of support and redistribute load. sp-foundation.org

8. Botulinum toxin–guided rehab blocks (as part of therapy planning).
   While botulinum toxin is a drug, the therapy plan around it (timed stretching, casting, gait training post-injection) is non-pharmacological structure that maximizes benefit. Purpose: focal tone reduction to unlock function. Mechanism: period of lowered muscle overactivity permits better motor relearning. Wiley Online Library+1

9. Serial casting & night splinting (short blocks).
   Used after stretching or injections to gradually lengthen tight calves/hamstrings. Purpose: prevent contractures and improve dorsiflexion. Mechanism: prolonged low-load stretch remodels connective tissue. PMC

10. Balance & fall-prevention training.
    Exercises for reactive stepping, dual-tasking, and home hazard reduction. Purpose: fewer falls and injuries. Mechanism: improve anticipatory and reactive postural control. PMC

11. Bladder-training & pelvic-floor therapy.
    Timed voiding and pelvic-floor exercises can reduce urgency/frequency. Purpose: improve continence and sleep. Mechanism: behavioral retraining of detrusor–sphincter function. nhs.uk

12. Speech & swallowing therapy (if dysarthria/dysphagia).
    Articulation drills, pacing, and safe-swallow strategies. Purpose: clearer speech and safer eating. Mechanism: motor-learning and compensatory techniques. PMC

13. Fatigue management & energy conservation.
    Pacing activities, micro-breaks, and task simplification. Purpose: maintain work/school participation. Mechanism: load management reduces neuromuscular overactivity. National Organization for Rare Disorders

14. Aquatic therapy.
    Warm-water buoyancy reduces tone and joint load, allowing longer practice with less pain. Purpose: endurance and flexibility. Mechanism: hydrostatic pressure + warmth decrease spasticity. PMC

15. Body-weight–supported treadmill or over-ground systems.
    Harness unloading allows safer stepping practice with less scissoring. Purpose: gait quality and endurance. Mechanism: graded unloading and repetitive stepping. Frontiers

16. Home safety modifications.
    Grab bars, non-slip mats, adequate lighting, and clutter reduction. Purpose: fewer falls. Mechanism: environmental risk control. sp-foundation.org

17. Pain management with heat, positioning, and gentle massage.
    Purpose: reduce secondary musculoskeletal pain from spastic postures. Mechanism: heat and gentle soft-tissue work decrease reflex hyperactivity. PMC

18. Mental health support & counseling.
    Living with progressive disability is stressful; counseling helps coping and adherence. Purpose: better quality of life and participation. Mechanism: cognitive-behavioral tools and social support. thebraincharity.org.uk

19. Nutrition & bone health strategies.
    Calcium/vitamin D and weight-bearing (as tolerated) to protect bone; hydration and fiber for bowel regularity. Purpose: reduce fractures/constipation risks. Mechanism: supports musculoskeletal and autonomic health. NINDS

20. Genetic counseling.
    Explains inheritance, recurrence risk, and testing options for relatives. Purpose: informed family planning. Mechanism: risk assessment based on autosomal-recessive CAPN1 variants. Orpha

---

Drug treatments

1. Baclofen (oral).
   Class: GABA_B agonist antispastic. Typical dose: start 5 mg 3×/day; titrate to effect (commonly up to 80 mg/day divided). Timing: with meals; slow titration. Purpose: reduce generalized spasticity and spasms. Mechanism: decreases excitatory neurotransmitter release in spinal cord. Side effects: drowsiness, weakness, dizziness; do not stop abruptly (withdrawal can be dangerous). Evidence from multiple FDA baclofen labels. FDA Access Data+2FDA Access Data+2

2. Intrathecal baclofen (LIORESAL® INTRATHECAL).
   Class: GABA_B agonist via pump. Dose: screening bolus followed by continuous infusion via implanted pump; microgram/day titration by specialists. Purpose: severe, refractory spasticity when oral baclofen is ineffective or not tolerated. Mechanism: delivers baclofen directly to spinal receptors with fewer systemic effects. Side effects: overdose/withdrawal risks, catheter/pump complications—specialist monitoring essential. FDA Access Data+1

3. Tizanidine (Zanaflex®).
   Class: α2-adrenergic agonist antispastic. Dose: start 2 mg; increase in 2–4 mg steps up to 36 mg/day in divided doses. Timing: consistent with/without food. Purpose: reduce spasticity and spasms, often for “peak-need” times. Mechanism: presynaptic inhibition of motor neurons. Side effects: hypotension, dry mouth, sedation; strong CYP1A2 interaction. FDA Access Data+1

4. Dantrolene (Dantrium®).
   Class: Peripherally acting muscle relaxant. Dose: often 25 mg daily, titrating to 25–100 mg 3–4×/day (specialist guidance). Purpose: reduces malignant muscle overactivity. Mechanism: inhibits calcium release from sarcoplasmic reticulum in muscle. Side effects: hepatotoxicity risk—monitor LFTs; weakness. FDA Access Data

5. OnabotulinumtoxinA (Botox®) — focal spasticity.
   Class: Neuromuscular blocker. Dose: individualized by muscle; lower-limb spasticity dosing ranges and maps provided in label; reinject every ~12 weeks. Purpose: targets problem muscles (e.g., calves, hip adductors) to improve positioning and therapy gains. Mechanism: blocks acetylcholine release at neuromuscular junction. Side effects: local weakness; rare systemic spread warnings. FDA Access Data+1

6. Gabapentin (Neurontin®).
   Class: α2δ ligand (antiepileptic/neuropathic pain). Dose: often titrated 300 mg to 1800–3600 mg/day in divided doses. Purpose: neuropathic pain or dysesthesias that can accompany spastic gait. Mechanism: modulates calcium channels to dampen abnormal excitability. Side effects: dizziness, somnolence, edema. FDA Access Data

7. Pregabalin (Lyrica®/Lyrica CR®).
   Class: α2δ ligand. Dose: commonly 150–300 mg/day (up to 600 mg/day), divided. Purpose: neuropathic pain and sleep improvement. Mechanism: reduces calcium-channel–mediated neurotransmitter release. Side effects: edema, weight gain, dizziness; dose-adjust in renal impairment. FDA Access Data+2FDA Access Data+2

8. Duloxetine (Cymbalta®).
   Class: SNRI antidepressant/neuropathic pain agent. Dose: 30–60 mg daily (up to 120 mg/day). Purpose: neuropathic pain, mood symptoms that worsen coping with disability. Mechanism: increases spinal descending inhibitory neurotransmission. Side effects: nausea, BP changes, withdrawal if stopped abruptly; note recent nitrosamine-related recalls of some lots (risk management is manufacturer-specific). FDA Access Data+2FDA Access Data+2

9. Oxybutynin ER (Ditropan XL®).
   Class: Antimuscarinic for overactive bladder. Dose: ER 5–30 mg once daily. Purpose: urgency/frequency/urge incontinence. Mechanism: M3 antagonism reduces detrusor overactivity. Side effects: dry mouth, constipation, cognitive effects (use caution in older adults). FDA Access Data+1

10. Mirabegron (Myrbetriq®).
    Class: β3-adrenergic agonist for overactive bladder. Dose: 25–50 mg once daily (granules/oral suspension options exist). Purpose: bladder urgency/frequency when antimuscarinics are not tolerated. Mechanism: relaxes detrusor during storage phase. Side effects: may raise blood pressure—monitor. FDA Access Data+1

11. OnabotulinumtoxinA — neurogenic detrusor overactivity.
    Class: Neuromuscular blocker. Dose: bladder injection dosing per label in patients refractory to anticholinergics. Purpose: reduce incontinence episodes in neurogenic bladder. Mechanism: blocks cholinergic signaling in detrusor. Side effects: urinary retention; UTI risk. FDA Access Data

12. Dalfampridine (Ampyra®).
    Class: Potassium-channel blocker. Dose: 10 mg twice daily (12 h apart). Purpose: improve walking speed in demyelinating conditions; sometimes tried off-label in spastic gait disorders under specialist care. Mechanism: prolongs action potentials to enhance conduction in impaired axons. Side effects: seizure risk (contraindicated with history of seizures or significant renal impairment). FDA Access Data+1

(If you’d like, I can add more symptomatic options—e.g., low-dose benzodiazepines, venlafaxine, solifenacin, baclofen granules/solutions labels—using FDA sources.)

---

Dietary molecular supplements

(General education; not disease-modifying + check interactions.)

1. Vitamin D3. Supports bone health when mobility is reduced; helps prevent fractures from falls. Mechanism: improves calcium absorption and bone mineralization; may support muscle function. Typical supplemental dose 800–2000 IU/day unless a clinician prescribes differently after testing. NINDS

2. Calcium (diet ± supplement). Works with vitamin D to maintain skeletal strength; reduces fracture risk with adequate intake and weight-bearing as tolerated. Dose: meet daily recommended intake via food first; supplement only if dietary intake is low. Mechanism: mineral substrate for bone. NINDS

3. Magnesium. May help muscle cramps and bowel regularity. Dose often 200–400 mg elemental magnesium/day (varies by salt form and tolerance). Mechanism: modulates neuromuscular excitability and smooth-muscle function. NINDS

4. Omega-3 fatty acids (fish oil). May support cardiovascular health and mild anti-inflammatory effects, helpful in sedentary states. Typical combined EPA+DHA 1 g/day from diet or supplements. Mechanism: eicosanoid pathway modulation. NINDS

5. Fiber (psyllium or diet). Improves constipation related to reduced mobility/anticholinergics. Dose: 10–20 g/day with fluids. Mechanism: stool bulk/gel formation improving transit. NINDS

6. Cranberry extract (adjunct). For recurrent UTIs, some patients use standardized cranberry; evidence mixed. Dose varies by product. Mechanism: proanthocyanidins may limit bacterial adhesion. NINDS

7. Coenzyme Q10. Popular for fatigue; evidence is limited in HSP, but generally well tolerated. Dose: 100–200 mg/day with fat-containing meals. Mechanism: mitochondrial electron transport support. NINDS

8. Creatine monohydrate. May aid short bursts of strength training during rehab. Dose: 3–5 g/day maintenance. Mechanism: phosphocreatine energy buffering for muscle contractions. NINDS

9. Probiotics. Sometimes used to offset constipation/anticholinergic GI effects. Dose: per product CFU; choose clinically studied strains. Mechanism: microbiome modulation. NINDS

10. Electrolyte solutions (oral rehydration). Useful during hot weather or after therapy to limit cramp triggers. Mechanism: maintain sodium/potassium balance and hydration. Dose: per label, avoid excess sodium with hypertension. NINDS

---

Immunity-booster / regenerative / stem-cell” drugs

(There are no FDA-approved disease-modifying or stem-cell drugs for CAPN1-HSP. Items below are conceptual/experimental—not routine care; dosing is investigational or not established for HSP.)

1. Gene-targeted therapy concepts (AAV or mRNA). Aim: restore calpain-1 function in neurons. Mechanism: deliver a working CAPN1 or modulate downstream pathways. Status: preclinical/early research only; no clinical dosing for HSP. PMC

2. Neurorehabilitation-driven plasticity (“functional regeneration”). High-intensity task practice can drive cortical-spinal re-mapping despite axonal disease. Mechanism: activity-dependent synaptic plasticity; “regenerative” in function if not structure. Frontiers

3. Mesenchymal stem-cell infusions (experimental). Investigated in other spastic disorders; not approved for HSP. Mechanism: paracrine anti-inflammatory and trophic signaling; dosing varies by trial and is not standard. PMC

4. Neuromodulation (investigational). Noninvasive brain or spinal stimulation paired with gait practice to boost motor learning. Mechanism: modulates excitability to reinforce desired motor patterns. Early-phase only. Frontiers

5. Calpain pathway modulators (research). Small molecules aimed at normalizing calcium-activated protease activity. Mechanism: restore downstream signaling balance; no approved drugs for SPG76. PMC

6. Exoskeleton-assisted gait training. Device-enabled stepping to increase repetition safely, potentially enhancing neuroplasticity. Dosing = session schedules; not a drug. Frontiers

---

Surgeries/procedures

1. Intrathecal baclofen pump implantation. A neurosurgeon places a programmable pump and spinal catheter after a positive test dose. Why: continuous, targeted baclofen for severe generalized spasticity with fewer systemic effects than high-dose oral therapy. FDA Access Data

2. Selective focal tendon lengthening (e.g., Achilles, hamstrings, hip adductors). Orthopedic release of chronically shortened tendons. Why: improve foot clearance, stance, and brace fit when conservative measures fail. Law Centre Northern Ireland

3. Soft-tissue releases with postoperative casting/therapy. Combined procedures to correct fixed contractures. Why: restore neutral joint position to enable safer walking/standing. Law Centre Northern Ireland

4. Botulinum toxin injection under EMG/ultrasound guidance (procedure). Precisely targets overactive muscles. Why: relieve focal spasticity that blocks gait training or hygiene. FDA Access Data

5. Bladder botulinum injection (for neurogenic detrusor overactivity). Cystoscopic injection into the bladder wall. Why: reduce refractory incontinence after medication failure. FDA Access Data

---

Prevention strategies

1. Daily stretching to prevent contractures. PMC

2. Routine PT/OT review to tune braces and exercises. nhs.uk

3. Fall-proof the home; use the right mobility aid early. sp-foundation.org

4. Keep vaccines current; manage UTIs promptly. NINDS

5. Maintain bone health (vitamin D, calcium, weight-bearing as able). NINDS

6. Schedule bladder routines; consider pelvic-floor therapy. nhs.uk

7. Protect skin (cushions, pressure relief) during prolonged sitting. PMC

8. Heat management and hydration to limit spasm triggers. NINDS

9. Regular medication reviews for interactions (e.g., tizanidine–CYP1A2). FDA Access Data

10. Genetic counseling for family planning. Orpha

---

When to see a doctor

See a clinician urgently for new or rapidly worsening weakness, frequent falls, severe spasms unresponsive to your usual plan, fever with suspected UTI, sudden bladder retention, swallowing trouble with choking, unintentional weight loss, new numbness, or severe depression/anxiety. Arrange routine reviews every 6–12 months (or sooner with changes) to adjust therapy, braces, and bladder plans, and to check bone health and medication side effects. Genomics Education Programme+1

---

What to eat” and “what to avoid

Eat:
• Hydrating fluids and high-fiber foods (vegetables, fruits, whole grains) for bowel regularity.
• Calcium- and vitamin-D-rich foods (dairy or fortified alternatives) for bones.
• Lean protein to support muscle maintenance alongside therapy.
• Omega-3-rich fish (e.g., sardines, salmon) for cardiometabolic health.
• Balanced meals to stabilize energy for therapy days. NINDS

Avoid/limit:
• Dehydration (worsens cramping and constipation).
• Excess alcohol (falls, sleep disruption).
• High-salt sports drinks if you have hypertension.
• Highly processed foods low in fiber (constipation).
• “Miracle” supplements promising cures without evidence. NINDS

---

FAQs

1. Is CAPN1-HSP curable? Not yet; care is symptomatic and preventive. Genomics Education Programme

2. Will everyone with CAPN1 variants develop ataxia? No—phenotypes vary from “pure” spasticity to complex forms with ataxia. Frontiers

3. How is it diagnosed? Clinical exam + exclusion of mimics + genetic testing confirming bi-allelic CAPN1 variants. ScienceDirect

4. Do brain scans always show abnormalities? Often normal or subtle findings; MRI mainly rules out other causes. PMC

5. What helps most day-to-day? Consistent PT/OT, stretching, and the right brace or cane/walker. nhs.uk

6. Are antispastic pills safe long-term? They can help, but monitoring for side effects (sedation, liver risks with dantrolene, BP changes with tizanidine) is essential. FDA Access Data+1

7. Is botulinum toxin useful? Yes for focal problematic muscles; evidence is growing and it’s widely used in spasticity care. Wiley Online Library+1

8. What if pills don’t work? Consider intrathecal baclofen pump evaluation in a spasticity center. FDA Access Data

9. Can walking speed improve? Sometimes—with therapy and, in selected cases, dalfampridine under specialist oversight. FDA Access Data

10. What about mood and fatigue? Treat pain and sleep; consider counseling and (when indicated) medications like SNRIs under medical guidance. FDA Access Data

11. Does diet change the disease? No, but smart nutrition supports therapy, bone health, and bowel/bladder routines. NINDS

12. Are stem cells an option now? Not established for HSP; use only in approved trials. PMC

13. How often should braces be reviewed? At least yearly or with any change in gait or skin issues. nhs.uk

14. Is CAPN1-HSP life-threatening? Most people have normal life expectancy but variable disability; falls and complications drive risk. Genomics Education Programme

15. Can family members be tested? Yes—after counseling, relatives can consider carrier or diagnostic testing. Orpha

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: October 13, 2025.